Cancer Immunology Unit, Department of Immunology & Histocompatibility, School of Medicine, University of Thessaly, University Hospital of Larissa, GR-411 10 Larissa, Greece.
J Exp Clin Cancer Res. 2010 Jun 4;29(1):64. doi: 10.1186/1756-9966-29-64.
This study aimed to examine whether EBV seropositive patients with lung cancer have an altered virus-specific CTL response, as compared to age-matched healthy controls and whether any variation in this response could be attributed to senescence.
Peripheral blood mononuclear cells from lung cancer patients, age-matched and younger healthy individuals were used to measure EBV-specific CTLs after in vitro amplification with the GLCTLVAML and RYSIFFDYM peptides followed by HLA-multimer staining.
Lung cancer patients and aged-matched controls had significantly lesser EBV-specific CTL than younger healthy individuals. Multimer positive populations from either group did not differ with respect to the percentage of multimer positive CTLs and the intensity of multimer binding.
This study provides evidence that patients with lung cancer exhibit an EBV-specific CTL response equivalent to that of age-matched healthy counterparts. These data warrant the examination of whether young individuals have a more robust anti-tumor response, as is the case with the anti-EBV response.
本研究旨在比较肺癌患者与年龄匹配的健康对照者之间 EBV 血清阳性患者的病毒特异性 CTL 反应是否存在差异，并探讨这种反应的变化是否与衰老有关。
使用体外扩增的 GLCTLVAML 和 RYSIFFDYM 肽以及 HLA 多聚体染色，从肺癌患者、年龄匹配的年轻健康个体的外周血单核细胞中测量 EBV 特异性 CTL。
与年轻健康个体相比，肺癌患者和年龄匹配的对照组的 EBV 特异性 CTL 明显减少。无论是哪一组，多聚体阳性群体的多聚体阳性 CTL 百分比和多聚体结合强度均无差异。
本研究提供的证据表明，肺癌患者的 EBV 特异性 CTL 反应与年龄匹配的健康对照者相当。这些数据提示我们需要进一步研究年轻人是否具有更强的抗肿瘤反应，就像针对 EBV 的反应一样。
